



Mitra
Keluarga

PT Mitra Keluarga Karyasehat Tbk.

1H 2025 Company Presentation



Forward Looking Statement

This presentation has been prepared for informational purposes only by PT Mitra Keluarga Karyasehat Tbk (“Mitra Keluarga” or the “Company”) and solely for use in connection with the Company’s update on its unaudited March 31, 2025 results. The information contained in this presentation has not been independently verified. No representation, warranty or undertaking, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or the opinions contained herein. None of the Company or any of their respective affiliates, and their respective commissioners, directors, employees, advisors or representatives shall have any liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this presentation or its contents or otherwise arising in connection with the presentation. Any decision to purchase or subscribe for securities of the Company should not be made on the basis of the information contained in this presentation. The presentation is not an offer of securities for sale in the United States or elsewhere. Securities may not be offered or sold in the United States or elsewhere absent registration or an exemption from registration. This presentation and its contents are confidential unless they are or become generally available as public information in accordance with prevailing laws and regulations (other than as a result of a disclosure by you) and must not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other person. This presentation does not constitute a recommendation regarding the securities of the Company. This presentation, including the information on the unaudited financial results of the Company and the projected financial results of the Company, and opinions contained herein, is provided as of the date of this presentation and is subject to change without notice, including change as a result of the issuance of the March 31, 2025 unaudited results of the Company. This presentation includes “forward-looking statements”. These statements contain the words “anticipate”, “believe”, “intend”, “estimate”, “expect” and words of similar meaning. All statements other than statements of historical facts included in this presentation, including, without limitation, those regarding the Company’s financial position, business strategy, plans and objectives of management for future operations (including development plans, objectives relating to the Company’s products and services and anticipated product launches) are forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as at the date of this presentation. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of risks, uncertainties and assumptions. Although the Company believes that such forward-looking statements are based on reasonable assumptions, it can give no assurance that such expectations will be met. You are cautioned not to place undue reliance on these forward looking statements, which are based on current views of the Company’s management on future events. Market data and certain industry forecasts used in this presentation were obtained from market research, publicly available information and industry publications which have not been independently verified, and no representation is made as to the accuracy of such information.

Section 1

Company Overview

PT Mitra Keluarga Karyasehat Tbk.



Key Investment Highlights



Mitra Keluarga at Glance

Leading Indonesian Hospital Group at a Glance



Business Line Up



Main Hospital Brand



Second Hospital Brand



Pet Hospital & Clinic

21 Hospitals

Full Blown Hospital
Strategic Geographical Focus
State of the Art Medical Facilities

10 Hospitals

Compact Hospital
Government Insurance Focus

1 Hospital

4 Clinics
Innovative Pet Healthcare in Prime Locations.

Supported by

4,160

Operational Beds

1,8K+

Specialist

A Leading and Trusted Hospital Provider

3.0 M+

OP Visit Served Annually

300 K +

IP Admission Served Annually

Strong Profitabilty & Financial Position

IDR 2.46 Bn+

Net Cash
(FY 2024)

37.7 %

EBITDA Margin
(FY 2024)

39.5 %

ROIC Exclude Land Bank
(FY 2024)



Highly Experienced and Qualified Management Team

Board of Directors



Rustiyan Oen
President Director

- 26 years at Mitra Keluarga
- 30 years of experience in the healthcare industry
- Education:
 - Bachelor: Bogor Institute of Agriculture (IPB)
 - MBA: San Diego State Uni.



Joyce V. Handajani
Director

- 10 years at Mitra Keluarga ⁽¹⁾
- 29 years of experience in the healthcare industry
- Education:
 - Bachelor: Uni. of Texas, Austin
 - MBA: Uni. of Texas, San Antonio



dr. Christina D. Anggraeni
Director

- 14 years at Mitra Keluarga
- 14 years of experience in the healthcare industry
- Education:
 - Medicine: State University of Sebelas Maret

Regional Director



dr. Arina Yuli Roswiyati
Regional I Director

- 13 years at Mitra Keluarga
- 25 years experience in healthcare industry
- Education:
 - Medicine: Diponegoro Uni.
 - MSc: University of Indonesia
 - MARS : University Of Respati Indonesia



dr. Sri Mawarti
Regional II Director

- 14 years at Mitra Keluarga
- 14 years of experience in the healthcare industry
- Education:
 - Medicine: University of Wijaya Kusuma
 - Master of Law: University of Wijaya Kusuma



dr. Carla Permanasari R.
Regional III Kasih Director

- 16 years at Kasih Group
- 25 years of experience in the healthcare industry
- Education:
 - Medicine: State University of Sebelas Maret
 - MM: University of Prasetya Mulya

Excellent Track Record


- Track record of profitability across all hospitals within 1 year of operation
- Effectively navigated Mitra Keluarga through the 1998 Asian Financial Crisis
- Established governance and oversight framework delivers growth while maintaining high quality service level
 - Consistent set of Key Performance Indicators (KPIs) applied across all hospitals
 - Monitored on a monthly basis

Exceptional Management

- Our leadership team brings diverse and highly relevant experience with in-depth knowledge about the healthcare industry
- Average of 22 years of healthcare experience
- Loyal and dedicated to Mitra Keluarga

(1) Previously with Kalbe Group for 19 years
(2) Based on the AGMS held on June 4, 2024

Strong Track Record of Over 35 Years




For over 35 years, we have delivered both strong growth and profitability through best-in-class operations, operational excellence and well-executed expansion


Strategic Location Focus

Attractive Economic and Demographic Fundamentals of Greater Jakarta and Surabaya Market

19% of Indonesia's Population in 2023



31% of Indonesia's GDP in 2023



With Highest Availability of Healthcare Professionals

No. of Doctors per 1,000 Population (2023)



Source: Badan Pusat Statistik Indonesia (Indonesian Statistical Center) – Total Population in Indonesia 275,773.8 thousand, Kementerian Kesehatan RI (Ministry of Health Indonesia) – Total Doctor in Indonesia 230,564



Located in Areas with Large, Attractive, Captive Population Catchment Areas and Highest Supply of Medical Graduates in Indonesia



Strategically located compact hospitals enabling access to underserved cities and serving mostly Government Health Insurance (JKN) patients which allows the Company to tap into smaller cities with less doctor supply

(1) Greater Jakarta comprises of Jakarta, Bogor, Depok, Tangerang, and Bekasi
(2) Data as of 2023 (Source : Badan Pusat Statistik)
(3) Data as of December 2023

Delivering Exceptional Patient Care Through Comprehensive Services at Leading Community Hospitals

Comprehensive Service Offerings

General services

- Laboratory
- Pharmacy
- Radiology
- Emergency Room
- Intensive Care Unit (ICU) Rooms

Focus specialty areas

- General Surgery
- Obstetrics & Gynecology
- Cardiovascular
- Neurosurgery
- Internal Medicine
- Pediatrics
- Oncology
- Urology
- Orthopedics

Other specialty areas

- Acupuncture
- Allergy & Immunology
- Anesthesiology
- Breast
- Cosmetic / Reconstructive Surgery
- Dental
- Dermatology
- Diabetes & Thyroid
- Ear, Nose & Throat
- Endoscopy
- Fertility
- Hematology
- Medical Rehabilitation
- Nephrology
- Nutrition Consultant
- Ophthalmology
- Pediatric Foot
- Pediatric Surgery
- Psychiatry
- Psychology
- Pulmonology
- Sleep Disorders
- Slimming & Health Sport Therapy
- Women's and Children Clinic

A Well-Established Center of Excellence



High-complexity specialty services contribute
over 25% of Total Revenue



Presidential Suite



SVIP



VIP



Class I



Class II



Class III

Cater to a wide spectrum
of patient across income
levels

Superior Ramp-up in New Hospitals



Mitra Keluarga Pamulang

- Opening January 2, 2023
- Total Bed Capacity: \pm 110
- Operational Bed: 102

EBITDA
Break even
 ± 3 Months

Current Net Profit
/ Loss
Profit



Mitra Keluarga Slawi

- Opening January 10, 2023
- Total Bed Capacity: \pm 120
- Operational Bed: 112

EBITDA
Break even
 ± 9 Months

Current Net Profit
/ Loss
Profit




Mitra Keluarga Grand Wisata

- Opening November 25, 2023
- Total Bed Capacity: \pm 154
- Operational Bed: 102


EBITDA
Break even
 ± 3 Months

Current Net Profit
/ Loss
Profit

Proven Capability to Attract and Retain Top-Tier Healthcare Professionals




Top Performer in Private Patient Revenue



High Doctor Retention Rate



Number of Full Time Specialist



Employee Composition by Age

Effective Recruitment Efforts

- Working environment that is conducive to learning given high patient volumes and our commitment to technology-enabled working facilities
- Attractive compensation structure includes revenue-sharing arrangement to align the interests of Mitra Keluarga and our doctors
- We believe we are an “Employer of Choice” for doctors and our senior doctors’ professional networks

(1) Includes both full and part time specialists and doctor.
Specialist doctors are typically independent doctors, not employed directly by us.
Full-time specialists work at least 40 hours per week at our hospitals and part-time specialists work less.

Long-standing Relationships with Our Doctors

- Continuous investment in their professional development through trainings, mentorships and scholarships
- High patient volumes and established track record contributes to strong financial compensation and employment stability for doctors
- A significant proportion of our general practitioners who pursue further studies return to practice with us after completion of studies (based on available vacancy)

Key Awards and Accolades

We are consistently recognized for excellence by leading national and international institutions by domestic and international institutions alike

Indonesia Corporate Brand Champion
2024
awarded by Transvision & Infobrand

Top Executive Award 2024
awarded by Transvision & Infobrand

52 Index
awarded by Tempo IDN Financial

Garda Medika Best Provider
for Mitra Keluarga Bintaro, Kemayoran, Cikarang,
Kenjeran Bekasi Timur, Waru, Tegal

Admedika Best of the Best Provider
for Mitra Keluarga Bekasi, Bekasi Timur, Cikarang

Top Corporate Award 2024
awarded by Transvision & Infobrand

Certificate of Appreciation for Best Service
Hospital Partner
awarded by BCA Life

Yakes Telkom Best Partner
for Mitra Keluarga Bekasi, Depok, Bekasi Timur

Mandiri Inhealth Best Prescription Achievement of
Inhealth Drug Formulary I in 2024
for Mitra Keluarga Tegal



Section 2

Key Growth Strategies



Capacity Expansion

No	Hospital	Site Identified	Land Banks	Construction Permits Secured	Hospitals in Construction	Initial Bed Capacity ⁽¹⁾	Max Bed Capacity ⁽²⁾	Capex Required ⁽³⁾ (± in Rp bn)	Expected Opening
1	Site 1	✓	✓	✓	✓	50-60	200	>250	2025
2	Site 2	✓	✓	✓	✓	50-60	200	>500	2026
3	Site 3	✓	✓	✓	✓	50-60	200	>200	2026
4	Site 4	✓	✓	—	—	50-60	200	>200	-
5	Site 5	✓	✓	—	—	50-60	200	>200	-
6	Site 6	✓	✓	—	—	50-60	200	>200	-
7	Site 7	✓	✓	—	—	50-60	200	>200	-
Total Pipeline Beds							1,400		
Additional Bed Capacity in Existing Hospitals as of Jun 30 th , 2025							857		
Potential Bed Addition							2,257		

- (1) New hospital starts with 50-60 operational beds initially, gradually adjusting bed capacity as demand rises
 (2) Estimation number of beds
 (3) Capex for building construction and major equipment (exclude Land, unless otherwise stated)




Groundbreaking Site 2



Groundbreaking Site 3

Capacity Expansion




3.0-5.0%


Additional Capacity
from Greenfield &
Brownfield
Expansion for 2025

Intensity Expansion

ARPIP




ARPOP




Mitra Keluarga continues to maintain its strong presence in the private patient business while embracing JKN segment

Expanding high-intensity specialty areas by establishing additional centers of excellence and expanding our subspecialist lineup.

FY 2016
Before Entering JKN Segment



FY 2024



FY24 : 85,2% Private Patient's Revenue Contribution



Section 3 Business Update



Grand Opening Kasih Hospital - Lemahabang



Kasih Hospital



Opening	26 June 2025
Max Bed Capacity	±100 Beds
Location	West Java

Hospital Under Developments



Site 1 - Mitra Keluarga Hospital

Estimated Opening	Q3 2025
Max Bed Capacity	±200 Beds
Location	East Java
Current Progress	93%



Site 2 – Mitra Keluarga Hospital

Estimated Opening	Q3 2026
Max Bed Capacity	±200 Beds
Location	Greater Jakarta
Current Progress	29%

Hospital Under Developments



Site 3 - Mitra Keluarga Hospital

Estimated Opening	Q3 2026
Max Bed Capacity	±200 Beds
Location	East Java
Current Progress	25%

Upgrading Existing Hospital Facilities to Improve Patient Experience



Specialist Clinic



Waiting Room



IP & OP Counter



Pediatric Center Lobby



Pediatric Center Clinic



VIP Ward



VIP Room



VIP Room



Rehab Center



Waiting Room



Specialist Clinic



MRI

As part of our strategic initiatives, we are focused on renovating and upgrading aging hospital facilities to improve the overall patient experience.



Completed Project	Ongoing Project
6 MIKA Hospitals	5 MIKA Hospitals
8 Kasih Hospitals	-



Advancing Integrated Cancer Care with Comprehensive Oncology Services



PET/CT
(On Progress)



SPECT/CT
(On Progress)



Radiotherapy
(Fully Operational since 2024)

Nuclear Medicine Center Mitra Keluarga Bekasi Timur

Estimated Opening Q3 2025

Location Greater Jakarta

Current Progress 100%

Comprehensive Oncology Services

Mitra Keluarga offers a fully integrated oncology service line, covering the entire patient journey—from early diagnosis to advanced treatment.

By combining clinical excellence with advanced technology, we deliver precise, personalized, and effective cancer care across our network.

Our services include:

- Diagnostic Imaging (PET CT)
- Chemotherapy
- Radiotherapy
- Nuclear-based Therapies (Theranostics)

Minimally Invasive Relief for BPH Patients



Mitra Keluarga Kelapa Gading rezūm

Rezūm Water Vapor Therapy adalah tindakan non-bedah yang menggunakan uap air, untuk menghilangkan jaringan prostat berlebih yang menekan uretra.

Mengatasi keluhan seperti:

- Sering Buang Air Kecil
- Mengejan saat Berkemih
- Pancaran Air Seni Melemah
- Sulit Menahan Buang Air Kecil

Rezūm Water Vapor Therapy

- Minimal invasive
- Quick & easy Procedure (10 minutes)
- Fast Recovery
- Low Risk of side effects
- Long-Lasting result

Advancing Orthopedic Surgery with Robotics



Mitra Keluarga Kelapa Gading **ROSA®** IS COMING TO Mitra Keluarga Kelapa Gading

The First Robotic Orthopedics Surgical Assistant in JAKARTA.

Find us on Social Media **Mitra Keluarga** @ Instagram Facebook Twitter YouTube

Robotic Orthopedics Surgical Assistant

- Minimal invasive
- More Precise
- Faster Recovery
- Customized for each patient
- Low Risk Of Complications
- More Natural Movement

Section 4

FINANCIAL PERFORMANCES



Key Performance Indicator



		1H24	1H25	YoY
Revenue by patient type (Rp Bn)	Inpatient	1.680	1.743	3,7%
	Outpatient	772	821	6,3%
	Total	2.452	2.563	4,5%
Operational Metrics	No. of Inpatient Admission ('000)	163	147	-9,7%
	No. of Outpatient Visits ('000)	1.487	1.391	-6,4%
	Patient Volume ('000)	1.650	1.538	-6,8%
	No. of Inpatient Days ('000)	455	418	-8,1%
	No. of Operational Beds	3.974	4.160	4,7%
	Bed Occupancy Rate (BOR)	62,9%	55,5%	-7,4%
	Average Length of Stay (ALoS)	2,8	2,8	1,8%
	Revenue per Inpatient Day (IDR'000)	3.696	4.169	12,8%
	Revenue per Outpatient Visit (IDR'000)	519	590	13,6%
Profitability (Rp Bn)	EBITDA ⁽¹⁾	936	991	5,8%
	% Margin	38,2%	38,6%	0,5%
	EBITDAR ⁽²⁾	944	991	5,0%
	% Margin	38,5%	38,6%	0,2%
	ROIC ⁽³⁾	25,6%	26,9%	1,3%
	ROIC – Exclude Land Bank ⁽⁴⁾	41,9%	44,0%	2,1%
	Net Income	645	684	6,0%
	% Margin	26,3%	26,7%	0,4%

Note:

(1) EBITDA refers to income before depreciation, provision of future employee benefits, allowance for impairment in value, corporate income taxes and other expenses and/or income (consisting primarily of administration fees of credit card providers and interest on bank loans)


(2) EBITDAR calculated as EBITDA plus rental and profit sharing expenses

(3) ROIC calculated as (Income from Operations – Tax) divided by Average (Total Debt + Total Equity – Cash)


(4) ROIC calculated as (Income from Operations – Tax) divided by Average (Total Debt + Total Equity – Cash – Land Bank – Advance for Land Bank)

%Revenue Contribution by Payer Mix

1H 2024




1H 2025




In 1H25, the contribution of private revenue continued to strengthen, increasing from 84.9% to 87.9%.

Non JKN Revenue





JKN Revenue




Private revenue posted a solid growth of 8.2%, while BPJS revenue declined by 15.1%, reflecting the company's strategic focus on strengthening the private segment

Revenue by Inpatient and Outpatient Services


Revenue Breakdown by Services



Inpatient Services Typically Account for Two-Thirds of Total Revenue



Additional Capital Expenditure




Calculated by additional cash flow

Cash Flow: Efficient Working Capital Management




Trade Receivables Days ⁽¹⁾

(Days)




Inventory Days ⁽²⁾

(Days)




Trade Payables Days ⁽³⁾

(Days)



Cash Cycle Days ⁽⁴⁾

(Days)




- (1) Calculated by dividing average trade receivables by revenue per day
(2) Calculated by dividing average inventories by cost of revenue (drugs and medical supplies, medical support services) per day
(3) Calculated by dividing average trade payables by cost of revenue (drugs and medical supplies, medical support services) per day
(4) Calculated by inventory days plus trade receivables days, less trade payable days

Section 4
APPENDIX
FINANCIAL INFORMATION




PROFIT & LOSS



Consolidated Statement of Income	30 June 2025 (Un-audited)	30 June 2024 (Un-audited)	% Change
REVENUES	2.563.460.446.888	2.452.497.795.842	4,5%
COST OF REVENUES	(1.161.547.053.864)	(1.134.324.537.309)	2,4%
<i>% to Revenues</i>	45,3%	46,3%	
GROSS PROFIT	1.401.913.393.024	1.318.173.258.532	6,4%
<i>% to Revenues</i>	54,7%	53,7%	
Operating expenses	(611.238.830.317)	(562.991.047.393)	8,6%
<i>% to Revenues</i>	-23,8%	-23,0%	
Other operating income	17.231.959.936	23.181.460.700	-25,7%
<i>% to Revenues</i>	0,7%	0,9%	
Other operating expenses	(2.698.406.163)	(445.912.318)	505,1%
<i>% to Revenues</i>	-0,11%	-0,02%	
INCOME FROM OPERATIONS	805.208.116.480	777.917.759.521	3,5%
<i>% to Revenues</i>	31,4%	31,7%	
Finance income	64.255.844.778	45.130.402.340	42,4%
Finance cost	(7.622.384.822)	(8.701.658.165)	-12,4%
INCOME BEFORE INCOME TAX	861.841.576.436	814.346.503.696	5,8%
<i>% to Revenues</i>	33,6%	33,2%	

PROFIT & LOSS

Consolidated Statement of Income	30 June 2025 (Un-audited)	30 June 2024 (Un-audited)	% Change
INCOME TAX – NET	(178.211.140.830)	(169.304.803.262)	5,3%
<i>% to Revenues</i>	<i>7,0%</i>	<i>6,9%</i>	
INCOME FOR THE YEAR	683.630.435.606	645.041.700.434	6,0%
<i>% to Revenues</i>	<i>26,7%</i>	<i>26,3%</i>	
Other comprehensive income - net of tax	732.090.100	-	#DIV/0!
TOTAL COMPREHENSIVE INCOME FOR THE YEAR	684.362.525.706	645.041.700.434	6,1%
<i>% to Revenues</i>	<i>26,7%</i>	<i>26,3%</i>	
Income for the year attributable to:			
Equity holders of the parent entity	639.725.007.180	600.565.094.997	6,5%
Non-controlling interests	43.905.428.426	44.476.605.437	-1,3%
Total	683.630.435.606	645.041.700.434	6,0%
Total comprehensive income for the year attributable to:			
Equity holders of the parent entity	640.267.470.192	600.565.094.997	6,6%
Non-controlling interests	44.095.055.514	44.476.605.437	-0,9%
Total	684.362.525.706	645.041.700.434	6,1%
Basic earnings per share attributable to equity holders of the parent entity	46	43	6,6%




BALANCE SHEET



Consolidated Balance Sheets	30 June 2025 (Un-audited)	31 December 2024 (Audited)	% Change
ASSETS			
CURRENT ASSETS			
Cash and cash equivalents	2.241.324.009.402	1.067.636.241.316	109,93%
Short-term investment	507.244.865.000	1.364.394.865.000	-62,82%
Trade receivables	860.085.390.748	723.194.941.498	18,93%
Other receivables	-	-	-
Third parties	55.242.351.413	48.919.738.767	12,92%
Related parties	1.807.750.056	830.083.344	117,78%
Other current financial assets	72.236.868.630	30.000.000.000	140,79%
Inventories	59.217.529.234	62.671.989.340	-5,51%
Prepaid tax	25.294.844	148.124.559	-82,92%
Advances and prepaid expenses	61.244.293.415	19.137.065.768	220,03%
Other Current Assets	1.818.006.381	3.595.530.748	
TOTAL CURRENT ASSETS	3.860.246.359.123	3.320.528.580.340	16,25%
TOTAL NON-CURRENT ASSETS	5.128.762.811.808	4.926.660.326.940	4,10%
TOTAL ASSETS	8.989.009.170.931	8.247.188.907.280	8,99%

BALANCE SHEET

Consolidated Balance Sheets	30 June 2025 (Un-audited)	31 December 2024 (Audited)	% Change
LIABILITIES			
CURRENT LIABILITIES			
<u>Trade payables</u>			
Third parties	189.527.690.489	171.763.689.988	10,34%
Related parties	44.318.522.365	44.186.853.677	0,30%
<u>Other payables</u>			
Third parties	105.932.507.655	96.053.334.051	10,29%
Related parties	2.305.479.955	2.149.501.621	7,26%
Dividend Payable	598.021.704.500	-	#DIV/0!
Advances from patients	30.583.462.904	28.570.171.987	7,05%
Accrued expenses	261.862.960.246	246.642.133.807	6,17%
Taxes payable	117.432.244.163	109.917.500.116	6,84%
Lease Liabilities	1.146.717.864	1.146.717.864	0,00%
TOTAL CURRENT LIABILITIES	1.351.131.290.141	700.429.903.111	92,90%
NON-CURRENT LIABILITIES	224.456.647.995	216.313.627.627	3,76%
TOTAL LIABILITIES	1.575.587.938.136	916.743.530.738	71,87%




BALANCE SHEET



Consolidated Balance Sheets	30 June 2025 (Un-audited)	31 December 2024 (Audited)	% Change
EQUITY			
<u>Equity attributable to equity holders of the parent entity</u>			
Share capital - par value of Rp10 per share			
Authorized - 50,000,000,000 shares	139.074.815.000	139.074.815.000	0,00%
Issued and fully paid - 13,907,481,500 shares			
Additional paid-in capital	606.031.284.612	606.031.284.612	0,00%
Other component of equity	1.011.642.661	117.378.864	761,86%
Retained earnings - appropriated	89.610.027.500	78.146.486.386	14,67%
Retained earnings - unappropriated	5.704.710.071.576	5.673.927.846.998	0,54%
Total equity attributable to equity holders of the parent entity	6.540.437.841.349	6.497.297.811.860	0,66%
Non-controlling interests	872.983.391.446	833.147.564.682	4,78%
TOTAL EQUITY	7.413.421.232.795	7.330.445.376.542	1,13%
TOTAL LIABILITIES AND EQUITY	8.989.009.170.931	8.247.188.907.280	8,99%

CASH FLOW



Consolidated Statement of Cash Flows	30 June 2025 (Un-audited)	30 June 2024 (Un-audited)	% Change
CASH FLOWS FROM OPERATING ACTIVITIES			
Cash receipts from customers	2.428.583.288.556	2.398.607.640.400	1,2%
Cash receipts from finance income	64.255.844.778	45.130.402.340	42,4%
Cash paid to suppliers	(1.540.308.560.453)	(1.511.390.742.655)	1,9%
Cash paid to employees and other operating expenses			-
Cash paid for finance cost	(7.622.384.822)	(8.701.658.165)	-12,4%
Cash paid for corporate income tax	(206.620.639.200)	(152.438.353.044)	35,5%
Net Cash Provided by Operating Activities	738.287.548.859	771.207.288.876	-4,3%
CASH FLOWS FROM INVESTING ACTIVITIES			
Placement of other current financial assets	(42.035.000.000)		-
Advances for acquisition of fixed assets			-
Payable for acquisition of fixed assets	(47.303.431.765)	(44.470.463.234)	6,4%
Placement of short-term investment	857.150.000.000	365.685.000.000	134,4%
Acquisition of fixed assets	(335.098.676.825)	(302.195.221.568)	10,9%
Proceeds from sale of other current financial assets		73.629.550.000	-100,0%
Proceeds from disposal of fixed assets	4.720.643.567	2.804.196.882	68,3%
Acquisitions of intangible assets	(176.805.289)	(827.741.336)	-78,6%
Net Cash Used in Investing Activities	437.256.729.688	94.625.320.744	362,1%

CASH FLOW



Consolidated Statement of Cash Flows	30 June 2025 (Un-audited)	30 June 2024 (Un-audited)	% Change
CASH FLOWS FROM FINANCING ACTIVITIES			
Payment for transfer of shares from Non-Controlling Interests	(491.510.461)		-
Payment of cash dividend			-
Payment of cash dividends to non-controlling interests	(1.365.000.000)	(5.999.916.954)	-77,2%
Capital Contribution From Non-Controlling Interests		13.600.000.000	-
Net Cash Provided (Used) in Financing Activities	(1.856.510.461)	7.600.083.046	-124,4%
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	1.173.687.768.086	873.432.692.666	34,4%
CASH AND CASH EQUIVALENTS AT BEGINNING OF YEAR	1.067.636.241.316	842.757.489.558	26,7%
CASH AND CASH EQUIVALENTS AT END OF PERIOD	2.241.324.009.402	1.716.190.182.224	30,6%

THANK YOU

PT Mitra Keluarga Karyasehat Tbk

Jl. Pengasinan, Rawa Semut, Margahayu

Bekasi Timur 17113, Indonesia

Phone : (62 21) 8999 7111

E-mail : corporate.secretary@mitrakeluarga.com

investor.relations@mitrakeluarga.com

Website : investor.mitrakeluarga.com

To subscribe please scan this barcode or go to our website

